|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.16 USD | -3.76% |
|
-5.29% | -15.27% |
| 30/05 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
| 30/05 | Canaccord Genuity Starts Coverage on TriSalus Life Sciences With Buy Rating, $12 Price Target | MT |
TriSalus Life Sciences, Inc. provided sales guidance for the full year of 2024. For the year, the company expects sales growth to exceed 50%.
| 1st Jan change | Capi. | |
|---|---|---|
| -15.27% | 194M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
TRISALUS LIFE SCIENCES, INC. 
